Research and clinical trials

Longer-term data help patients and clinicians understand whether an initial response to a new biologic (mirikizumab) is likely to last and whether safety findings remain acceptable over two years.

A validated AI biomarker that predicts which IBD treatments are likely to work could reduce trial-and-error in treatment choices, potentially shortening time to effective therapy for people with Crohn's disease or...

Cure8 found this source from eagletribune.com, but the page could not be read reliably yet. It is tagged for Crohn's disease, Inflammatory bowel disease, and Research and clinical trials. Open the original article for...

Cure8 found this source from youtube.com, but the page could not be read reliably yet. It is tagged for Crohn's disease, Inflammatory bowel disease, and Mirikizumab. Open the original article for the full details.

People with Crohn’s disease who have an ileostomy have limited noninvasive ways to monitor small-bowel inflammation. This study suggests measuring fecal calprotectin from ileostomy output could help detect postoperative...

Market reports highlight which companies and drug types are investing in Crohn's disease — that can signal upcoming therapies, trial activity, and availability. Mentions of trials (for example anti‑TL1A) may be of...

Cure8 found this source from sciencedirect.com, but the page could not be read reliably yet. It is tagged for Crohn's disease, Inflammatory bowel disease, and Research and clinical trials. Open the original article for...

Based on the title and source metadata, this appears to be a clinical study related to Crohn's disease, Inflammatory bowel disease, and Diet and lifestyle. The original article is from msn.com.

Cure8 found this source from onlinelibrary.wiley.com, but the page could not be read reliably yet. It is tagged for Crohn's disease and Procedures and surgery. Open the original article for the full details.

People with both psoriasis and hidradenitis suppurativa appear to have higher overall morbidity and a greater observed risk of Crohn’s disease. Genetic findings suggest shared biological pathways that could affect how...

This reports a potential new way to extend remission after exclusive enteral nutrition by combining diet with fecal microbiome transfer—an approach that targets the gut microbiome rather than adding drugs. If effective,...

This story matters because it outlines a plausible way to extend the benefits of exclusive enteral nutrition (EEN) for Crohn's disease by using fecal microbiome transfer (FMT) to 'lock in' a healthier microbiome and...

This study tests whether a ‘microbiome reboot’ — using exclusive enteral nutrition followed by fecal microbiome transfer — can make the beneficial microbiome changes last longer and help keep Crohn’s disease in...

Cure8 could only read part of this source from eurekalert.org, so this card uses cautious topic tags instead of a full summary. It is tagged for Crohn's disease, Inflammatory bowel disease, and Research and clinical...

This study tests whether combining exclusive enteral nutrition with a follow-up fecal microbiome transfer can create a longer-lasting, less inflammatory gut microbiome — which could help maintain remission in Crohn’s...

Longer-term (two-year) results suggest mirikizumab (Omvoh) can maintain clinical and endoscopic benefits for many people with Crohn’s disease, including some with prior biologic failure, which is important when weighing...

This suggests an existing antibiotic, vancomycin, may help a specific group of IBD patients who also have primary sclerosing cholangitis (PSC), including some who did not respond to other IBD treatments. If confirmed in...

This study suggests a common genetic marker (HLA‑DQA1*05) may help explain why some children stop responding to anti‑TNF drugs and could eventually guide who might benefit from adding methotrexate or closer monitoring.

Long-term maintenance of clinical and endoscopic remission is a key goal in Crohn’s disease care. Positive two-year data and FDA approval may affect treatment options for adults, including people who previously failed...

These are multi‑year clinical results for a newly approved IL‑23p19 inhibitor (mirikizumab) showing sustained clinical and endoscopic benefit for many patients with moderate‑to‑severe Crohn’s disease, including some who...

Based on the title and source metadata, this appears to be a clinical trial phase 3 related to Crohn's disease, Inflammatory bowel disease, and Ustekinumab. The original article is from msn.com.

Based on the title and source metadata, this appears to be a basic science related to Inflammatory bowel disease and Research and clinical trials. The original article is from msn.com.

A noninvasive wearable that tracks inflammation markers could let people with IBD and their clinicians detect rising disease activity earlier and potentially act before symptoms develop. This may make monitoring less...

Cure8 found this source from medpagetoday.com, but the page could not be read reliably yet. It is tagged for Crohn's disease, Inflammatory bowel disease, and Diet and lifestyle. Open the original article for the full...

Long-term data matter because they show whether benefits and safety of a new biologic hold up beyond the initial trial period. For people with Crohn’s disease, sustained clinical remission and endoscopic healing are...

Based on the title and source metadata, this appears to be a clinical trial phase 2 related to Crohn's disease, Inflammatory bowel disease, and Research and clinical trials. The original article is from msn.com.

Durable treatment responses matter to people with Crohn’s disease because sustained clinical remission and endoscopic improvement can mean fewer symptoms and less inflammation over time. Longer safety and durability data...

This article reports two-year data showing that mirikizumab (Omvoh) maintained clinical and endoscopic benefit for many people with moderate–severe Crohn’s disease, and that results across Phase 3 programs also support...

Based on the title and source metadata, this appears to be a clinical trial phase 3 related to Crohn's disease, Inflammatory bowel disease, and Research and clinical trials. The original article is from msn.com.

This press release reports multi-year data suggesting many patients treated continuously with mirikizumab maintained clinical remission and endoscopic response at two years—outcomes people with Crohn’s disease often care...

Long-term results matter because they report whether an IL‑23 inhibitor (Omvoh) maintained clinical and endoscopic improvements through two years for people with moderate-to-severe Crohn’s disease, including some with...

This press release reports multi-year clinical trial data suggesting sustained remission and intestinal healing with Omvoh (mirikizumab) in patients with Crohn's disease—information that could affect treatment...

This roundup highlights new IBD research and real-world care issues that could influence future diagnosis, monitoring, and access to treatments. Findings on financial barriers and gaps in treat-to-target monitoring may...

This trial suggests a new IL‑23 inhibitor, mirikizumab, may be an effective and safe treatment option for adults with moderate-to-severe Crohn's disease who have not responded to prior therapies. Positive phase 3 results...

The article summarizes recent drug approvals and Phase 3 trial results that could affect which biologic treatments are available and how the Crohn's disease treatment market may change. It also gives epidemiology and...

Early-stage work on a new bispecific antibody could point to a different immune-regulatory approach for treating inflammatory bowel disease. Patients and clinicians watching IBD drug development may find the mechanism...

Cure8 could only read part of this source from einnews.com, so this card uses cautious topic tags instead of a full summary. It is tagged for Crohn's disease, Inflammatory bowel disease, and Research and clinical trials.

This article reports the start of a first-in-human trial testing extracellular vesicles as a new regenerative treatment for complex perianal fistulas in Crohn's disease, a hard-to-treat complication with limited options.

Researchers are exploring whether gut microbes differ in patients who develop fibrous strictures — a common, surgery-prone complication of Crohn’s disease — because that could help predict risk or point to new prevention...

This signals new investigational IBD research focused on a novel immune pathway (TL1A/DR3) that could lead to future treatments. For people with Crohn’s/IBD, it’s an early-stage development to watch, but not an immediate...

Researchers and companies continue exploring new immune-targeted therapies for IBD. A new DR3-targeted antibody could become a future treatment direction if clinical studies show benefit and safety. This announcement...

Based on the title and source metadata, this appears to be a market or business news related to Crohn's disease, Inflammatory bowel disease, and Risankizumab. The original article is from firstwordpharma.com.

This article describes implantable vagus nerve stimulators being studied as a way to reduce inflammation in autoimmune diseases, including Crohn’s disease. If effective, these devices could offer a non-drug option or...

Fundraising events like this support research and patient services for people with Crohn’s disease and ulcerative colitis. They also raise public awareness about IBD, which can reduce stigma and increase community...

New FDA approval adds another IL‑23p19 biologic option for moderate‑to‑severe Crohn’s disease and highlights two‑year efficacy data, which may affect treatment choices and future pediatric availability.

Based on the title and source metadata, this appears to be a biomarker study related to Inflammatory bowel disease, Colorectal Cancer Risk, and Research and clinical trials. The original article is from msn.com.

A test that more accurately predicts which IBD patients with pre-cancerous bowel changes will develop cancer could help target surveillance and treatment to those at higher risk and reduce unnecessary procedures for...

Based on the title and source metadata, this appears to be a market or business news related to Inflammatory bowel disease and Access, cost, and policy. The original article is from menafn.com.